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Abstract
Nanotechnology is a branch of science, which empowers innovation to discover new
medical technologies, improving current diagnostic and treatment methods. The scope
of nanotechnology focuses mainly on “technology transfer”, in which research aims to
facilitate the application of recent nanoscience techniques to conventional medicine
development methodologies. Nanomedicine is attractive to researchers who wish to target
speciﬁc infectious diseases associated with poverty, which is highlighted through the many
pertinent examples of recent breakthroughs in nanomedicine. An overview is provided in
this study to highlight the barriers and implementation of nanomedicine for various
infectious diseases in the African continent. Patient backgrounds provide the greatest of
challenges for new technologies in terms of improving bioavailability and dosage. This
review points out the current situation of nanomedicine in Africa and explores the
possibility of how nanomedicine could improve patient drug regimens and wellbeing.
Introduction
Nanomedicine is a science, which plays a crucial role in
both health and medicine. The term nanomedicine was
ﬁrst established in late 1990s, with publications emerg-
ing in the early to mid-2000s (Wagner et al., 2006). The
scope of nanomedicine research is impressive, having
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been studied widely across multiple applications.
Despite this, many experts are unable to provide a
uniform deﬁnition for nanomedicine to explain their
ﬁndings (Webster, 2006). Some authors’ deﬁnition is
born from the fact that since it is the study of particles
in the nanometre range, the range should therefore be
called the nanoscale or themselves be called nanoparti-
cles. The broad deﬁnition can be termed in relation to
their respective ﬁelds. For instance, researchers in
the ﬁeld of biological sciences extended their investi-
gations towards the ﬁeld of nanomedicine by providing
nanoparticles through proteins and nucleic acids
(Wagner et al., 2006).
The technology has been successful and revolution-
ary through the development of new drug products,
such as Doxil® (Sequus, Menlo Park, CA) (liposome
encapsulated Doxorubicin) and Abraxane® ( Abraxis
BioScience, Inc, New Zealand) (nanoparticle albumin–
bound paclitaxel) which are both on the market and
clinically available (Malam et al., 2009). Indeed, the
application in which medicine is integrated into a
nanoparticulate system allows researchers to investi-
gate drug delivery strategies more appropriately and
in greater detail. The growth in this technology has
been more rapid, whereas in the drug discovery sector
it is more challenging. Therefore, it is essential for re-
searchers to understand the clinical translation process
as currently the developed drug approval rate for phase
I clinical trials is low at around 10% (Hay et al., 2014).
Consequently, more insight into this technology in
terms of progression through clinical application will
lead to successful clinical translation strategies in the
early stages of research.
Notably, the scale of research in terms of drug devel-
opment and discovery will always be in contrast with
the volume of drugs, which enter into the market. This
issue arises as new drugs must be approved by various
clinical trial phases prior to entry in the market. Fur-
thermore, drugs need to be considered in relation to a
multitude of factors, such as toxicity, solubility, bio-
availability and efﬁcacy. Failure to address such factors
would reﬂect badly within the drug market in terms of
“poor compliance”. These issues are exempliﬁed in
Poverty Related Diseases (PRD), such as tuberculosis
(TB), malaria, and HIV. There are signiﬁcant factors
which must be considered as although appropriate
drugs are available in the market, poor drug adminis-
tration (both low and high) leads to increased patient
risk. Low drug solubility and bioavailability may result
in low drug uptake through poor administration, which
will lead to treatment failures as routes towards the
emergence of drug resistant strains would be provided.
The converse is also true through increased dosage
quantities and frequencies, which may be employed
to counter low drug solubility and bioavailability. This
would lead to alternative treatment failures, especially
when a physician prescribes drugs with respect to the
patient’s circumstances, as increased dosage and
prolonged treatment can impact patients in terms of
negative side effects. Hence, challenges in drug
development towards PRDs are considered to be a
critical issue, especially in developing countries
(Anwabani, 2002). As such, nanomedicine can play a
crucial role towards PRD in Africa, with technologies
aimed at targeting issues such as poor solubility and
limited bioavailability; the so called Class II, Class IV
drugs according to the Biopharmaceutics Classiﬁcation
System (BSC) (Amidon et al., 1995). To address these
challenges in the treatment of PRDs, the investigation
of nanomedicine by African researchers has revealed
promising approaches for improving treatments of TB,
HIV, malaria, etc. (Choonara et al., 2011). Through
consideration of this emerging ﬁeld of research and
development, effective drug technologies will be pro-
duced preventing life-threatening disease infections
for future generations.
Nanomedicine – The Scope of Poverty
Related Diseases (PRD)
Nanomedicine can be categorised as one of four types:
nanocarriers, polymer therapeutics, solid drug
nanoparticles (SDN), and inorganic nanoparticles (NPs)
(Niemirowicz et al., 2012; Busquets et al., 2015;
McDonald et al., 2015; Giardiello et al., 2016; Saravanan
et al., 2018). The conjugation between drugs and water-
soluble polymers is aimed at overcoming bioavailability is-
sues through drug encapsulation onto nanoparticle sur-
faces or within nanocarriers. This conjugation between
the drug and nanocarrier can be simply intermolecular or
as a covalent linkage, which is cleaved as the nanocarrier
arrives at its target site allowing the drug to dissociate
from the nanocarrier, offering controlled release.
Nanomedicine has many impressive applications in
drug product development and research (Etheridge et
al. 2013). This technology has a great implication in
the design of personalised medicine that promises diag-
nostic methods and the ability to effectively treat pa-
tients individually. The primary beneﬁts are related to
drug dosage and treatment times, which can be
lowered for more effective therapy with fewer side
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effects. This greater effectiveness is achieved through
targeting drug conjugated nanoparticle to increase
drug uptake speciﬁc to the individual, which both en-
hances systemic concentrations and residence times
(Wang et al., 2011).
Furthermore, nanoparticles have the signiﬁcant po-
tential to be targeted speciﬁcally to the disease recep-
tors. The binding takes place both actively or passively
through bioconjugation of antibodies and speciﬁc
ligands (McCarron et al., 2008; Kamaly et al., 2012).
This mode of target speciﬁc drug release would give
rise to an overall increase in the blood circulation time
of the drug (Kamaly et al., 2012). There are several ad-
vances in nanomedicines targeted at passage through
the blood brain barrier (BBB) and ﬁne capillary blood
vessels, which in turn offers improved drug uptake
across other barriers (e.g., lung and intestinal) (D Jong
and Borm, 2008; Onoue et al., 2014).
Signiﬁcantly, nanomedicine has great applicability
towards early stage diagnostics of cancer. This is
achieved through semiconductor devices designed to
image the ﬂuorescence (Farias et al., 2009) of samples
either within blood or speciﬁc tissues. This challenge
plays a crucial role in reduction of cancer related death
rates (Niemirowicz et al., 2012; Choudhary and Kusum
Devi, 2015). The advancement in early diagnosis is more
accurate and patients will be highly beneﬁted both ﬁ-
nancially and through reduced treatment times and
medication (Pericleous et al., 2012). Navalakhe and
Nandedkar, 2007 reported that the small size and large
surface area of nanoparticles increases their ability to
interact internally within cell surfaces (Clift et al.,
2008). The phenomenon in terms of tumour tissue accu-
mulation is referred as “Enhanced Permeability and Re-
tention” (EPR) effect. Therefore, similar approaches in
terms of cellular and tissue accumulation of drugs spe-
ciﬁc to PRDs will have advantages in terms of treatment
of bacterial infections like TB (Meerovich et al., 2008).
African Perspective of Nanomedicine
In order to enhance the global contribution of African
countries in the ﬁeld of nanotechnology, the
Nanosciences African Network (NANOAFNET) was
established in 2005, with around 27 African countries
engaged in this network. In the case of nanomedicine,
their activities focus on the improvement of therapies
for infectious diseases related to poverty, including
TB, malaria, HIV, etc. Moreover, in 2011 the CSIR
(Council for Scientiﬁc and Industrial Research)
Nanomedicine Platform in South Africa hosted the ﬁrst
“International Workshop on Nanomedicine for Infec-
tious Diseases of Poverty”. Importantly, the CSIR
Nanomedicine Platform in South Africa collaborated
actively with the “Pan-African Centre of Excellence
in Nanomedicine” to discuss the application of
nanomedicine research and training, in partnership
with industry and academia, to signiﬁcantly enhance
the development of therapeutic compounds for infec-
tious diseases of poverty (Chang et al., 2015).
The need is signiﬁcant. Around 6million people are af-
fected annually, many of whom losing their lives, due to
the poor compliance with the aforementioned diseases.
According to theWorld Health Organisation (WHO), 2010
Global TB report, one third of the world’s population is
currently infected with Mycobacterium tuberculosis.
Additionally, an estimated 1.7 million people died from
TB in 2009 with the highest number of deaths occurring
in Africa (Global Tuberculosis control, WHO report,
2010). Malaria remains one of the world’s most preva-
lent infectious diseases, with 40% of the world’s popula-
tion at risk of infection. In 2009, there were an
estimated 225 million cases of malaria reported
worldwide and an estimated 781,000 deaths (WHO,
2010). Additionally, the somewhat neglected tropical
leishmaniasis affectsmore than 1 billion people annually
for those living in tropical and subtropical climates.
Additionally, a further 500,000 people are affected
annually with new cases of leishmaniasis arising in
Southeast Asia and East Africa (Davidson et al., 1996).
Speciﬁcally, visceral leishmaniasis is more life threaten-
ing in cases where no proper treatment is available. In
terms of HIV, Sub-Saharan Africa still bears the largest
global share of the burden, with the highest number of
people living with HIV as well as the highest number of
new HIV infections, AIDS-related deaths and the highest
adult HIV prevalence (UNAIDS, 2010). HIV infection
weakens the immune system and as such exposes the
patient to other infectious diseases such as TB, malaria
and leishmaniasis. Consequently, HIV is gaining popular-
ity for further investigations towards diagnosis as well as
therapeutic research.
The antimicrobial properties of nanomedicines have
been extensively investigated (Azam et al., 2012; Islam
et al., 2013; Neyrolles et al., 2013). Although there are
currently drugs available for the treatment of tubercu-
losis, the deep in-sights of their mechanism are yet to
be properly understood. Therefore, nanomedicine in
terms of anti-mycobacterial application needs more
investigation (Hussain et al., 2013). In 2001, Hussain
et al. reported on the accurate targeting and drug
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delivery applications of particles in both the micro and
nano size range, where nanoparticles were shown to
engulf and subsequently co-localise Mycobacterium
tuberculosis, which resides in macrophages, within
the micro-organism. Hence, the role of nanoparticles
has been understood, demonstrating the targeting of
speciﬁc sites instead of other sites (Hussain et al.,
2001). These ﬁndings have clearly shown that
nanomedicine has laid a foundation to the scientiﬁc
community for further improvements in the therapeu-
tic ﬁeld of TB. In the case of malaria, the encapsulation
of primaquine in liposomes and solid–lipid nanoparticles
has proven advantageous. Additionally, towards the
treatment of toxoplasmosis as well as leishmaniasis, a
recent study reported the effectiveness of silver nano-
particles (Islan et al., 2017). Speciﬁcally, silver NPs
can be prepared by using physical, chemical or biologi-
cal methods (Barabadi et al., 2017a, 2017b). However,
further investigations are required before these
products reach the market.
Adverse Effects or Limitations of
Nanomedicine to Patients
Kermanizadeh et al., 2014 reported that the mode of
action of nanoparticles related to toxicity has not been
extensively investigated. Bio-distribution studies have
shown that the liver is the primary site and exposure
route. Toxicity mainly exists through oxidative stress,
inﬂammation, ROS production, carcinogenicity and
genotoxicity (Johnston et al., 2015; Kermanizadeh
et al., 2014). Additionally, the route of administration
and size of the nanoparticle will also play a signiﬁcant
role in producing adverse effects (Kermanizadeh
et al., 2014).
Remarkably, more that 70% of the clinically available
nanomedicines are administered via non-patient-
friendly, intravenous routes leading to a reduction in
patient adherence to treatment. Furthermore, the
regulations for nanoproducts and nanomedicines
are still at a very early stage as traditional regulations
are not appropriate for nanoproducts. Consequently,
there is a signiﬁcant necessity for regulatory reform
in order to establish “nanoguidelines”, facilitating
the translation of nanomedicine from research
laboratories to the clinical market (Fornaguera and
García-Celma, 2017).
Conclusions
There is much to be investigated and learned from
nanomedicine and TB. This study provides the recent
updates from the previous literature and provides an
explanation of nanomedicine and its applications.
Combining the collective expertise from a range of dis-
ciplines is required to allow an amalgamated, coherent
and thorough evaluation of where the next steps of
research should be taken. A further understanding of
how drugs are penetrating the lung cavities is required
which may allow a more tailored nano-based regime to
be designed to exploit the unique properties NPs have
to offer. Faster disease diagnosis and initiation into
treatment programmes is paramount if TB is ever to
be controlled. Signiﬁcantly, a cohesive effort between
governments, funding bodies, scientists, clinicians and
patients akin is essential to combat this disease. In
conclusion, more screening of substances is required
to identify anti-mycobacterial compounds as MDR/XDR
TB levels escalate. Moreover, metal/metal oxide NPs
have the potential to be integrated into clinical medi-
cine. Hence, their inherent anti-bacterial properties
should be exploited.
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